New cancer drug targets specific tumor marker in early trial
NCT ID NCT05161390
Summary
This study tested an experimental drug called LM-302 in people with advanced solid tumors that have a specific protein marker (CLDN18.2). The main goals were to find a safe dose and see if the drug shows early signs of fighting the cancer. It involved 153 adults whose cancer had progressed despite standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai East Hospital
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.